Thermo Fisher Scientific Stock price
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
550.8 USD | -0.03% | -0.19% | +3.76% |
Financials (USD)
Sales 2023 | 42.86B | Sales 2024 * | 43.03B | Capitalization | 213B |
---|---|---|---|---|---|
Net income 2023 | 6B | Net income 2024 * | 6.37B | EV / Sales 2023 | 5.41 x |
Net Debt 2023 | 26.84B | Net Debt 2024 * | 22.52B | EV / Sales 2024 * | 5.47 x |
P/E ratio 2023 |
34.4
x | P/E ratio 2024 * |
33.6
x | Employees | 130,000 |
Yield 2023 * |
0.25% | Yield 2024 * |
0.27% | Free-Float | 87.27% |
Latest transcript on Thermo Fisher Scientific
1 day | -0.03% | ||
1 week | -0.19% | ||
Current month | +2.18% | ||
1 month | +1.25% | ||
3 months | +22.82% | ||
6 months | +0.63% | ||
Current year | +3.76% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 55 | 01-10-31 |
Director of Finance/CFO | 57 | 01-05-31 | |
Karen Nelson
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 55 | 01-10-31 |
C. Harris
BRD | Director/Board Member | 67 | 12-03-29 |
Ruby Chandy
BRD | Director/Board Member | 62 | 22-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.69% | 2 M€ | -25.75% | ||
7.43% | 19 M€ | +2.97% | - | |
5.37% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-02-09 | 550.8 | -0.03% | 1,280,838 |
24-02-08 | 550.9 | -0.26% | 1,549,469 |
24-02-07 | 552.3 | -1.42% | 1,451,424 |
24-02-06 | 560.3 | +1.57% | 1,328,171 |
24-02-05 | 551.6 | -0.04% | 1,473,858 |
Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.76% | 213 B $ | |
+5.02% | 180 B $ | |
+15.08% | 137 B $ | |
+13.30% | 95 956 M $ | |
+2.97% | 65 162 M $ | |
+11.49% | 51 559 M $ | |
+2.33% | 50 253 M $ | |
-4.09% | 39 074 M $ | |
+5.20% | 37 039 M $ | |
+7.33% | 27 162 M $ |